Medical devices, healthcare technology and the business of care
PMA approval · P250050

Liverty TIPS Stent Graft

Bard Peripheral Vascular, Inc. · Decision date Sep 25, 2026

FDA DECISIONP250050

What did the FDA approve?

FDA records P250050 as an original PMA application. The recorded decision is approval, dated Sep 25, 2026.

FDA approval order statement

Approval for the Liverty TIPS Stent Graft. The device is indicated for the treatment of complications of portal hypertension
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Sep 25, 2026

FDA source record

Regulatory record facts

Identifier
P250050
Regulatory pathway
Premarket approval application
Product code
MIR
Decision code
APPR
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS.

Product code
MIR
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250050 received

    Application receipt date recorded by FDA.

  2. P250050 · FDA decision

    APPR

  3. P250050/S001 · Related supplement

    Liverty TIPS Stent Graft

Timeline entries are records held by MedtechLedger for P250050. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250050

Product / regulatory recordCompanyPathwayDecision dateSource
Bard Peripheral Vascular, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bard Peripheral Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1625 W. 3rd St., Tempe, AZ, 85281

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records